{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Complete Hematologic Response is defined as: bone marrow evaluation shows \\<= 5% myeloblasts with normal maturation of all cells lines; peripheral blood evaluation shows hemoglobin \\>= 11 g/dL, neutrophils \\>= 1000/mL, platelets \\>= 100,000/mL, 0% blasts","groups":[{"description":"All participants enrolled.\n\n5-Azacitidine: Administered on Days 1-7 of each Cycle.\n\nSubcutaneous administration:\n\nTo provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.\n\nThe 5-azacitidine suspension is administered subcutaneously.\n\nIntravenous Administration:\n\n5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes.","id":"OG000","title":"Arm 1 - 5-Azacitidine"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Percentage of Patients With Complete Hematologic Response (According to IWG 2006 Criteria) in CMML Patients Treated With 5-azacitidine.","type":"PRIMARY","unitOfMeasure":"percentage of patients"}